Gasporox (GPX) Q2 2025 earnings summary

Executive summary

• Revenue for Q2 2025 was 6,864 KSEK, down from 9,675 KSEK year-over-year; operating result was -3,426 KSEK versus 12 KSEK last year.

• Cash flow for Q2 was -5,625 KSEK, with cash and equivalents at 12,308 KSEK at quarter-end.

• The company is focusing on broadening its offering and long-term customer value, with ongoing investments in new products and solutions.

• Order backlog remains healthy, with a major order delayed to Q3 due to customer payment timing.

• Service business is growing, and new product launches are expected after ongoing field tests.

Financial highlights

• Q2 net sales decreased 29% year-over-year to 6,864 KSEK; H1 net sales were 10,834 KSEK, down from 18,330 KSEK.

• Q2 operating result was -3,426 KSEK (12 KSEK last year); H1 operating result was -7,545 KSEK (237 KSEK last year).

• EBITDA for Q2 was -1,821 KSEK (1,400 KSEK last year); H1 EBITDA was -4,403 KSEK (2,806 KSEK last year).

• Cash flow for Q2 was -5,625 KSEK (254 KSEK last year); H1 cash flow was 5,496 KSEK (28 KSEK last year), supported by convertible loans.

• Equity at quarter-end was 19,208 KSEK, with a solidity of 37% (54% last year).

Outlook and guidance

• Management expects improved performance in the second half, supported by a strong order backlog and delayed orders now being delivered.

• The company continues to invest in R&D and product launches, aiming to become the standard for non-destructive quality control in pharma and food packaging.

• No additional capital is expected to be needed to reach positive cash flow, barring major market changes or accelerated expansion.